Gossamer Bio, Inc. (NASDAQ:GOSS) Sees Large Increase in Short Interest

Gossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 7,020,000 shares, a growth of 10.0% from the November 30th total of 6,380,000 shares. Based on an average trading volume of 1,290,000 shares, the days-to-cover ratio is currently 5.4 days.

Gossamer Bio Price Performance

Shares of GOSS traded up $0.03 during trading hours on Tuesday, reaching $0.90. 927,816 shares of the company traded hands, compared to its average volume of 1,478,089. The stock has a market capitalization of $204.99 million, a PE ratio of -2.83 and a beta of 1.85. The stock has a fifty day simple moving average of $0.81 and a 200 day simple moving average of $0.90. Gossamer Bio has a fifty-two week low of $0.50 and a fifty-two week high of $1.60. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. The firm had revenue of $9.48 million for the quarter, compared to analyst estimates of $4.52 million. As a group, research analysts predict that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Gossamer Bio in a report on Monday, November 11th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $9.20.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. NEA Management Company LLC boosted its holdings in shares of Gossamer Bio by 14.2% during the second quarter. NEA Management Company LLC now owns 18,093,034 shares of the company's stock worth $16,300,000 after purchasing an additional 2,255,025 shares during the last quarter. Monaco Asset Management SAM grew its holdings in Gossamer Bio by 390.3% in the 2nd quarter. Monaco Asset Management SAM now owns 2,726,104 shares of the company's stock valued at $2,456,000 after buying an additional 2,170,104 shares during the period. Marshall Wace LLP increased its stake in shares of Gossamer Bio by 170.8% during the 2nd quarter. Marshall Wace LLP now owns 3,335,511 shares of the company's stock valued at $3,002,000 after acquiring an additional 2,103,766 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Gossamer Bio by 204.7% during the 2nd quarter. Renaissance Technologies LLC now owns 2,046,600 shares of the company's stock valued at $1,844,000 after acquiring an additional 1,375,000 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of Gossamer Bio by 31.3% during the 2nd quarter. Acadian Asset Management LLC now owns 3,592,765 shares of the company's stock worth $3,235,000 after acquiring an additional 856,380 shares during the period. 81.23% of the stock is currently owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.